Daniel Aaron Vazquez-Matias

Daniel Aaron Vazquez-Matias

Auto-generated profile, based on publicly available information

Daniel Aaron Vazquez-Matias

Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 May 2025 in The Journal Of Prevention of Alzheimer's Disease
Verified
Journal Article
Open access
LKLotte A. de Koning
Lotte A. de Koning
DVDaniel A. Vazquez-Matias
Daniel A. Vazquez-Matias
WBWissam Beaino
Wissam Beaino
DVDaniëlle J. Vugts
Daniëlle J. Vugts
GDGuus A.M.S. van Dongen
Guus A.M.S. van Dongen
EGElsmarieke van de Giessen
Elsmarieke van de Giessen
The field of Alzheimer's disease (AD) drug development is rapidly changing, with two anti-amyloid monoclonal antibodies (mAbs) having received Food and Drug Administration (FDA) approval, additionally many compounds are in the pipeline. A major obstacle for novel AD therapeutics is the blood-brain barrier (BBB), which restricts passage of particles larger than 400-500 Da. It is estimated that only ∼0.1 % of mAbs, being ∼150 kDa, passes the BBB, which greatly hampers the efficacy of treatment. To enhance treatment efficacy and to lower the drug dose needed, mechanisms that effectively increase drug delivery across the BBB are urgently sought for. This narrative review describes three promising strategies to enhance drug delivery across the BBB in AD: focused ultrasound (FUS) with microbubbles, receptor-mediated transcytosis (RMT) and delivery using nanoparticle carrier systems. FUS and RMT have shown promising preclinical results and are now being tested in humans whereas nanoparticle carrier systems still need further preclinical validation before clinical application in humans. 89Zr-Immuno-PET provides a unique opportunity to noninvasively monitor and quantitatively assess novel brain delivery methods.

5 February 2024 in Neuropharmacology
Verified
Journal Article
Open access
KPKavya Prasad
Kavya Prasad
Erik de VriesErik de Vries
Erik de Vries
EMEsther van der Meiden
Esther van der Meiden
RMRodrigo Moraga-Amaro
Rodrigo Moraga-Amaro
DVDaniel Aaron Vazquez-Matias
Daniel Aaron Vazquez-Matias
AWAren van Waarde
Aren van Waarde
Adenosine A2A-receptors (A2AR) and dopamine D2-receptors (D2R) are known to work together in a synergistic manner. Inhibiting A2ARs by genetic or pharmacological means can relief symptoms and have neuroprotective effects in certain conditions. We applied PET imaging to evaluate the impact of the A2AR antagonist KW6002 on D2R availability and neuroinflammation in an animal model of Parkinson's disease. Male Wistar rats with 6-hydroxydopamine-induced damage to the right striatum were given 3 mg/kg of KW6002 daily for 20 days. Motor function was assessed using the rotarod and cylinder tests, and neuroinflammation and dopamine receptor availability were measured using PET scans with the tracers [11C]PBR28 and [11C]raclopride, respectively. On day 7 and 22 following 6-OHDA injection, rats were sacrificed for postmortem analysis. PET scans revealed a peak in neuroinflammation on day 7. Chronic treatment with KW6002 significantly reduced [11C]PBR28 uptake in the ipsilateral striatum [normalized to contralateral striatum] and [11C]raclopride binding in both striata when compared to the vehicle group. These imaging findings were accompanied by an improvement in motor function. Postmortem analysis showed an 84% decrease in the number of Iba-1+ cells in the ipsilateral striatum [normalized to contralateral striatum] of KW6002-treated rats compared to vehicle rats on day 22 (p = 0.007), corroborating the PET findings. Analysis of tyrosine hydroxylase levels showed less dopaminergic neuron loss in the ipsilateral striatum of KW6002-treated rats compared to controls on day 7. These findings suggest that KW6002 reduces inflammation and dopaminergic neuron loss, leading to less motor symptoms in this animal model of Parkinson's disease.

6 March 2024 in Radiotherapy and Oncology
Verified
Journal Article
Open access
DVDaniëlle Voshart
Daniëlle Voshart
MKMyrthe Klaver
Myrthe Klaver
YJYuting Jiang
Yuting Jiang
HWHilmar R.J. van Weering
Hilmar R.J. van Weering
FBFleur van Buuren-Broek
Fleur van Buuren-Broek
LBLara Barazzuol
Lara Barazzuol
Although proton therapy is increasingly being used in the treatment of paediatric and adult brain tumours, there are still uncertainties surrounding the biological effect of protons on the normal brain. Microglia, the brain-resident macrophages, have been shown to play a role in the development of radiation-induced neurotoxicity. However, their molecular and hence functional response to proton irradiation remains unknown. This study investigates the effect of protons on microglia by comparing the effect of photons and protons as well as the influence of age and different irradiated volumes. Rats were irradiated with 14 Gy to the whole brain with photons (X-rays), plateau protons, spread-out Bragg peak (SOBP) protons or to 50 % anterior, or 50 % posterior brain sub-volumes with plateau protons. RNA sequencing, validation of microglial priming gene expression using qPCR and high-content imaging analysis of microglial morphology were performed in the cortex at 12 weeks post irradiation. Photons and plateau protons induced a shared transcriptomic response associated with neuroinflammation. This response was associated with a similar microglial priming gene expression signature and distribution of microglial morphologies. Expression of the priming gene signature was less pronounced in juvenile rats compared to adults and slightly increased in rats irradiated with SOBP protons. High-precision partial brain irradiation with protons induced a local microglial priming response and morphological changes. Overall, our data indicate that the brain responds in a similar manner to photons and plateau protons with a shared local upregulation of microglial priming-associated genes, potentially enhancing the immune response to subsequent inflammatory challenges.

17 January 2026 in Psychiatry Research
Verified
Journal Article
Open access
DVDaniel A. Vazquez-Matias
Daniel A. Vazquez-Matias
Erik de VriesErik de Vries
Erik de Vries
CGCyprien Guerrin
Cyprien Guerrin
KPKavya Prasad
Kavya Prasad
JDJanine Doorduin
Janine Doorduin
This study aimed to investigate whether there are metabolic connectivity alterations in the brain of rats with a depressive-like phenotype, using positron emission tomography (PET) and graph theory methods. Male Wistar rats were exposed to 5 days of repeated social defeat (RSD) to induce a depressive-like phenotype, and brain connectivity was assessed with [18F]FDG-PET. Sucrose preference tests were conducted to assess anhedonia-like behaviour, a symptom of depression. The results showed that anhedonia-like behaviour was present one day after RSD and recovered after seven days. The analysis of large-scale brain networks revealed a reduction in connectivity in the default mode network of RSD-exposed animals one day after RSD, suggesting a link between reduced connectivity and the presence of anhedonia-like behaviour. Seven days after RSD, an increase in connectivity was observed in the salience network, which coincided with the recovery of sucrose preference. Modular analysis revealed different configurations of brain regions at one and seven days after RSD, with asymmetrical segregation of left and right hemisphere structures. These findings suggest that changes in brain connectivity may play a role in the development and recovery of anhedonia-like behaviour in rats exposed to RSD and may have implications for understanding depressive phenotypes.


1 December 2021 in European Neuropsychopharmacology
Verified
Journal Article
Closed access
KPK. Prasad
K. Prasad
EME. Van der Meiden
E. Van der Meiden
RMR. Moraga-Amaro
R. Moraga-Amaro
DVD.A. Vazquez-Matias
D.A. Vazquez-Matias
Erik de VriesErik de Vries
Erik de Vries
AWAren van Waarde
Aren van Waarde